thiophenes has been researched along with Parkinsonian Disorders in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, KL; Jackowiak, EM | 1 |
| Asanuma, M; Isooka, N; Kikuoka, R; Kitamura, Y; Miyazaki, I; Nakayama, E; Shin, K; Wada, K; Yamamoto, D | 1 |
| Frucht, S; Han, SC; Katus, L | 1 |
| Espay, AJ; Gupta, HV; Sharma, VD | 1 |
| Evans, RM; Martin, HL; Mounsey, RB; Mustafa, S; Nelson, MC; Sathe, K; Teismann, P | 1 |
| Bentley, MD; Brotchie, JM; Dizman, B; Eskow Jaunarajs, KL; Fang, Z; Hill, MP; Johnston, TH; Moreadith, RW; Ravenscroft, P; Standaert, DG; Viegas, TX; Weimer, R; Yoon, K | 1 |
| Binetti, G; Frisoni, GB; Moretti, DV; Zanetti, O | 1 |
| He, J; Tian, JW; Yao, JY; Yu, X | 1 |
| Alvarez-Fischer, D; Arias-Carrión, O; Borta, A; Djufri, M; Höglinger, GU; Keber, U; Oertel, WH; Ries, V; Scheller, D; Schwarting, RK; Windolph, A | 1 |
| Hiratochi, M; Ijiro, T; Kaidoh, K; Oana, F; Suzuki, T; Tsuchioka, A; Yamauchi, Y | 1 |
| Gerlach, M; Gruenblatt, E; Heindl, M; Lebsanft, H; Mayerhofer, A; Riederer, P; Scheller, DK; Schmidt, WJ | 1 |
| Domino, EF; Ni, L | 1 |
| Block, F; Dafotakis, M; Juzek, A; Kosinski, CM; Sparing, R | 1 |
| Mabrouk, OS; Marti, M; Morari, M; Volta, M | 1 |
| Baralatei, FT; Lauterbach, EC | 1 |
| Muqit, M; Sammler, EM; Stuart, A; Swingler, RJ | 1 |
| Burton, NC; Guilarte, TR; Kensler, TW | 1 |
| Bezard, E; Hill, M; Lübbert, H; Porras, G; Ravenscroft, P; Scheller, D; Stichel-Gunkel, C | 1 |
1 trial(s) available for thiophenes and Parkinsonian Disorders
| Article | Year |
|---|---|
Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Dopamine Agonists; Follow-Up Studies; Humans; Parkinsonian Disorders; Psychiatric Status Rating Scales; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2014 |
17 other study(ies) available for thiophenes and Parkinsonian Disorders
| Article | Year |
|---|---|
Severe parkinsonism caused by brexpiprazole: A case report.
Topics: Aged; Antidepressive Agents; Depression; Dopamine Agonists; Female; Humans; Parkinsonian Disorders; Quinolones; Thiophenes | 2019 |
Dopaminergic neuroprotective effects of rotigotine via 5-HT1A receptors: Possibly involvement of metallothionein expression in astrocytes.
Topics: Animals; Astrocytes; Cells, Cultured; Dopamine Agonists; Female; Male; Metallothionein; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Antagonists; Tetrahydronaphthalenes; Thiophenes | 2020 |
Dramatic Response to Pramipexole in Delayed-Onset Parkinsonism from Osmotic Demyelinating Syndrome.
Topics: Adult; Antiparkinson Agents; Deamino Arginine Vasopressin; Demyelinating Diseases; Dystonia; Epistaxis; Hemostatics; Humans; Hyponatremia; Levodopa; Locked-In Syndrome; Male; Myelinolysis, Central Pontine; Osmotic Pressure; Parkinsonian Disorders; Postoperative Hemorrhage; Pramipexole; Pseudobulbar Palsy; Rhinoplasty; Tetrahydronaphthalenes; Thiophenes; Treatment Failure; Treatment Outcome; von Willebrand Disease, Type 1 | 2020 |
Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia.
Topics: Adrenergic beta-Antagonists; Aged; Aripiprazole; Clonazepam; Deprescriptions; Depressive Disorder; Drug Substitution; GABA Modulators; Humans; Male; Parkinsonian Disorders; Pelvis; Propranolol; Quinolones; Serotonin Agents; Tardive Dyskinesia; Tetrabenazine; Thiophenes; Treatment Failure; Valine | 2020 |
A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Count; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Female; Glial Fibrillary Acidic Protein; Humans; Macrophage-1 Antigen; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neuroprotective Agents; Parkinsonian Disorders; PPAR delta; Rats; Sulfones; Thiazoles; Thiophenes; Tyrosine 3-Monooxygenase | 2013 |
Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Drug Delivery Systems; Female; Male; Motor Activity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2013 |
Protection of MPTP-induced neuroinflammation and neurodegeneration by rotigotine-loaded microspheres.
Topics: Animals; Antioxidants; Blotting, Western; Corpus Striatum; Cytokines; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Microspheres; MPTP Poisoning; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Tetrahydronaphthalenes; Thiophenes | 2015 |
A new dopaminergic nigro-olfactory projection.
Topics: Animals; Dopamine; Dopamine Agonists; Immunohistochemistry; Male; Neural Pathways; Neural Stem Cells; Neuroanatomical Tract-Tracing Techniques; Neurogenesis; Neuronal Tract-Tracers; Neurons; Olfaction Disorders; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Substantia Nigra; Tetrahydronaphthalenes; Thiophenes | 2015 |
Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions.
Topics: Animals; Antiparkinson Agents; Apomorphine; Azepines; Benzothiazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Ergolines; Indoles; Injections, Intraventricular; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Quinolines; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 2015 |
Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements.
Topics: Adrenergic Agents; Animals; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Tetrahydronaphthalenes; Thiophenes | 2008 |
Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Biperiden; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Female; Levodopa; Macaca nemestrina; Muscarinic Antagonists; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Tetrahydronaphthalenes; Thiophenes | 2008 |
Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis.
Topics: Administration, Cutaneous; Dopamine Agonists; Fear; Humans; Malabsorption Syndromes; Male; Middle Aged; Parkinsonian Disorders; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes | 2009 |
Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzamides; Bicuculline; Bridged Bicyclo Compounds, Heterocyclic; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; GABA Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Hindlimb Suspension; Male; Microdialysis; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Substantia Nigra; Thiophenes; Time Factors | 2008 |
Switching to duloxetine remits ziprasidone - associated urinary incontinence and improves neuropsychiatric behavior in dementia: possible relationship of incontinence to 5HT2 receptor blockade.
Topics: Aged, 80 and over; Alzheimer Disease; Dementia, Vascular; Duloxetine Hydrochloride; Humans; Male; Parkinsonian Disorders; Piperazines; Receptors, Serotonin, 5-HT2; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Thiazoles; Thiophenes; Urinary Incontinence | 2009 |
Dopamine dysregulation syndrome in a patient with early onset Parkinsonism and Parkin gene mutations.
Topics: Adult; Dopamine; Dopamine Agonists; Humans; Male; Metabolic Diseases; Mutation; Parkinsonian Disorders; Tetrahydronaphthalenes; Thiophenes; Ubiquitin-Protein Ligases | 2009 |
In vivo modulation of the Parkinsonian phenotype by Nrf2.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antineoplastic Agents; Autoradiography; Cocaine; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Iodine Isotopes; Male; Mice; Mice, Inbred ICR; Mice, Knockout; NF-E2-Related Factor 2; Parkinsonian Disorders; Phenotype; Thiones; Thiophenes | 2006 |
Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease.
Topics: Acute Disease; Administration, Cutaneous; Animals; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Iodine Radioisotopes; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Radioligand Assay; Receptors, Dopamine; Substantia Nigra; Tetrahydronaphthalenes; Thiophenes | 2008 |